Financial Modeling Prep·2026-03-10 18:15Core Insights - Tempus AI Inc. is a leader in AI-driven precision medicine, focusing on integrating AI technologies into healthcare to enhance patient outcomes [1] - The company collaborates with major pharmaceutical firms to improve the discovery and development of precision medicine biomarkers [1] Company Developments - On March 10, 2026, H.C. Wainwright set a price target of $95 for Tempus, indicating a potential increase of approximately 82.6% from its trading price of $52.03 [2] - Tempus has entered a strategic collaboration with Merck & Co. Inc. to advance AI-driven precision medicine, utilizing its advanced Lens Platform and significant GPU infrastructure for complex analyses [3] - This partnership aims to enhance Merck's oncology and broader therapeutic portfolios by identifying novel precision biomarkers and mechanisms of cancer cell resistance [4] Market Performance - Tempus' market capitalization is approximately $8.96 billion, with a trading volume of around 928,414 shares on NASDAQ [5] - The stock has fluctuated between a high of $104.32 and a low of $36.22 over the past year, despite recent declines coinciding with broader market sell-offs [4][5]